2013-03-16 11:26:38 - New Pharmaceuticals research report from GlobalData is now available from Fast Market Research

GlobalData has released its new PharmaPoint Drug Evaluation report, "Lyrica (Epilepsy) - Forecast and Market Analysis to 2022". Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However,

the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action.


Full Report Details at
- www.fastmr.com/prod/553312_lyrica_epilepsy_forecast_and_market_a ..


Lyrica is a compound with both analgesic and anticonvulsant properties that was developed by Pfizer as a more potent successor to gabapentin (Neurontin). Pregabalin is the active pharmaceutical ingredient in Lyrica, and it binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in CNS tissues. Blockade of these channels has been shown to inhibit the calcium-dependent release of a number of neurotransmitters. While pregabalin is a structural derivative of the inhibitory neurotransmitter GABA, it does not bind directly to GABA-A, GABA-B, or benzodiazepine receptors, and it does not augment GABA responses. Lyrica is available as both a capsule and solution for oral administration, and has been approved for the treatment of partial seizures, peripheral neuropathy (sensory neuropathy), fibromyalgia, postherpetic neuralgia (PHN), and diabetic neuropathy.

Scope

* Overview of Epilepsy, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Lyrica including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Lyrica for the top nine countries from 2012 to 2022.
* Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, China and India

Reasons to buy

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Epilepsy
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Lyrica performance
* Obtain sales forecast for Lyrica from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, China and India)

Report Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Classification of Seizures
3.2 Etiology and Pathophysiology
3.2.1 Etiology
3.2.2 Pathophysiology
3.2.3 Prognosis
3.2.4 Quality of Life
4 Disease Management
4.1 Diagnosis
4.2 Treatment Guidelines
4.3 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Lyrica (pregabalin)
6.1 Overview
6.2 Therapeutic Role
6.3 Efficacy
6.4 Safety
6.5 SWOT Analysis
6.6 Forecast
7 Appendix
7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
7.4.1 Prevalent Epilepsy Patients
7.4.2 Percent Drug-Treated Patients
7.4.3 General Pricing Assumptions
7.4.4 Individual Drug Assumptions
7.4.5 Generic Erosion
7.5 Physicians and Specialists Included in this Study
7.6 Primary Research - Prescriber Survey
7.7 About the Authors
7.7.1 Authors
7.7.2 Global Head of Healthcare
7.8 About GlobalData
7.9 Contact Us
7.10 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Epilepsy Syndromes by Age at Onset (2009 ILAE Classification)
Table 2: Classification of Seizures
Table 3: Etiology of Epilepsy According to Age
Table 4: Etiology of Partial Seizures
Table 5: Etiology of Generalized Seizures
Table 6: Some of the Genes Involved in Epilepsy
Table 7: Summary of Diagnostic Tools for Epilepsy
Table 8: Treatment Guidelines for Epilepsy
Table 9: AED Options by Seizure Type
Table 10: Top Three AEDs Prescribed for Epilepsy by Market
Table 11: Types of Epilepsy Surgery
Table 12: Leading Treatments for Epilepsy, 2012
Table 13: Product Profile - Lyrica
Table 14: Lyrica SWOT Analysis, 2012
Table 15: Global Sales Forecasts ($m) for Lyrica (pregabalin), 2012-2022
Table 16: Physicians Surveyed, By Country

List of Figures

1.2 List of Figures
Figure 1: Summary of the Pathophysiology of Seizures by Net Increased Neuronal Excitation
Figure 2: Mechanisms of Action of AEDs at the Synapse
Figure 3: AED Selection Based on Comorbidity

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.